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A B S T R A C T
Background/Aims: Strategies for an effective intervention after chronic kidney disease (CKD) screening have not
been well examined. We describe the rationale and design of a protocol of a pragmatic randomized controlled
trial (RCT) to test the effect of a behavioral intervention using the nudge approach in behavioral economics on
CKD patients’ visiting behaviors to physicians and change in their kidney function after CKD screening.
Methods: The RCT will include CKD patients (N= 4500) detected at screening (estimated glomerular filtration
rate [eGFR]<60mL/min/1.74m2 or urine protein≥1+), aged 40–63 years. The two intervention groups will
receive a “usual letter” and “nudge-based letter,” while the control group will only receive a conventional
follow-up. Our primary outcome is proportion of patients’ visiting physicians for 6 months after the intervention;
the secondary outcome is change in the eGFR at 2 years after the intervention.
Results: We developed an efficient intervention program after CKD screening and designed the pragmatic RCT to
assess its effectiveness in the real world. Our trial is unique in that it investigates the effect of the nudge approach
in behavioral economics. By the end of 2018, we have enrolled 1,692 participants, and randomized 677 par-
ticipants into the usual letter group, 677 participants into the nudge-based letter group, and 338 participants into
the control group. We have confirmed that health checkup data could identify a large number of eligible par-
ticipants.
Conclusion: The trial's results will contribute to filling in the gap between screening and subsequent medical
interventions for preventing CKD progression.
1. Introduction
Chronic kidney disease (CKD) is recognized as a major public health
burden because it is associated with cardiovascular disease and mor-
tality, as well as progression to end-stage renal disease (ESRD) [1–3].
From the perspective of health care resource utilization, a severer CKD
stage is associated with higher health care cost, which is a big burden
for society and the health care system [4,5]. Therefore, prevention of
CKD progression is required worldwide. The first step for prevention is
to identify potential CKD patients from the general population. Previous
studies reported a substantial prevalence of CKD in the general popu-
lation [2]; for example, 13% in Japan [6] and 11% in the United States
[7].
There is a large gap between the number of potential CKD patients
estimated from the laboratory results at screening and the number of
diagnosed CKD patients extracted from medical records. This gap
means that many of the potential CKD patients do not visit physicians to
receive care for CKD. In Japan, where large-scale CKD screening is
performed within the health care system [8], it is possible to clarify the
actual CKD prevalence during screening of the general population and
to track CKD patients' visiting behavior to physicians after CKD
screening. If CKD is suspected at the health checkup based on renal
function test results (urine test result and estimated glomerular filtra-
tion [eGFR]), it is recommended that patients visit a physician to
confirm the presence of CKD. To maximize the effect of screening on the
prevention of CKD progression, an effective intervention needs to be
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designed for patients suspected of having CKD in order to encourage
them to appropriately visit their physicians after screening. In con-
ventional follow-up after CKD screening in Japan, participants will be
notified of their results, but there is no special intervention for offering
CKD care. The intervention at that time is preferable to not be man-
datory; instead, a “nudge” that respects the patient's free will is re-
quired [9]. The idea of behavioral economics and nudge approaches to
healthcare is popular in public health [10].
In order to implement research to improve patients' visiting beha-
vior to physicians after CKD screening in the general population, we
launched the pragmatic trial of nudging CKD patients after screening.
The trial was designed in the Japanese health care system, which has
features of a universal health care system and large-scale CKD
screening. The aim of the trial is to evaluate whether a behavioral in-
tervention (i.e., a usual letter and nudge-based letter) would improve
CKD patients’ visiting behaviors to physicians and protect their kidney
function.
2. Methods
2.1. Overall study design
The pragmatic randomized controlled trial (RCT) of nudging CKD
patients after screening was designed in the health care system setting
[11] to examine the effect of a novel behavioral intervention among
CKD patients (Fig. 1). We will identify CKD patients at screening and
randomize them into three groups: “usual letter,” “nudge-based letter,”
and control group. Between the groups, we will compare outcomes of
patients’ visiting behaviors to physicians (visiting physicians for CKD
care for 6 months after the intervention) and change in their kidney
function (change in the eGFR after 2 years).
2.2. Participants and setting
We conducted this pragmatic RCT among persons insured by the
Health Insurance Association for Architecture and Civil Engineering
companies in Japan (HIA2CE), which is a large health insurance asso-
ciation that insures about 400,000 persons as employees and their fa-
mily members. The health insurance association covers most of the
architecture and engineering companies all over Japan, from local
small construction companies to major general contractors.
The inclusion criteria are (a) age between 40 and 63 years, (b)
patients receiving CKD screening, and (c) those with an eGFR<60mL/
min/1.74m2 or positive proteinuria. Proteinuria was measured by a
urine dipstick test as −, ± , 1+, or 2+. Results of urine protein
≥1 + were defined as positive proteinuria. The exclusion criteria are
(a) patients with an eGFR<15 mL/min/1.74 m2, and (b) those with
ESRD. Those criteria will be confirmed using health checkup data from
April 2018 to March 2019. The eGFR will be estimated from annual
health checkup data using the Japanese coefficient-modified CKD
Epidemiology Collaboration equation, which has been validated in the
Japanese population [12,13].
2.3. Intervention and control
We defined two intervention groups that will receive a notification
letter, the usual letter and nudge-based letter. We also defined a third
group as the control group that will not receive a letter. Data collectors
and those assessing outcomes will be blinded to the assignment of in-
terventions.
In the usual letter, we provide information about CKD based on
clinical evidence; recommend visits to physicians; and show patients'
individual health checkup results of the eGFR, urine protein, and risk
factors of hypertension (systolic blood pressure/diastolic blood pressure
≥140/90mmHg or receiving antihypertensive drugs), diabetes (gly-
cated hemoglobin A1c level ≥6.5% or receiving antidiabetic drugs),
and smoking (current smoker or not). In the nudge-based letter, we
encourage visits to physicians using the nudge approach in behavioral
economics. The nudge is defined as “any aspect of the choice archi-
tecture that alters people's behavior in a predictable way without for-
bidding any options or significantly changing their economic in-
centives” [9]. In general, behavioral economics researchers consider
people's seemingly irrational behaviors, procrastination [14] and loss
avoidance [15], to construct a nudge-based intervention. In this study,
to alter the participant's visiting behavior to physicians in a clinically
desirable way without forbidding any other options, our nudge ap-
proach includes “commitment” (designing the space for intentions
prompts, where participants write the visiting date and time, solidifying
their intention of visiting physicians, and preventing the procrastina-
tion) [16] and “loss-framed message” (considering loss avoidance and
giving information that emphasizes the loss of opportunity for pre-
venting CKD progression and for work) [17]. We also add information
about the concrete steps to visit a physician in order to decrease the
participant's burden (cognitive costs). We also show individual health
checkup results in the nudge-based letter as in the usual letter. The
volumes of documents are similar between both the nudge-based letter
and usual letter. Supplemental Fig. 1 and Supplemental Fig. 2 show the
format of these letters. These letters will be sent by mail to individuals
from the health insurance association. The research team is not in-
volved in the individual shipping business of personal data, and the trial
is open-labeled without blinding because it would be difficult to send a
placebo letter to the control group.
Conventional follow-up after the screening will be implemented in
all groups including the control group. In the Japanese health checkup
Fig. 1. Overall study design. The pragmatic randomized controlled trial of
nudging CKD patients after screening was designed in the health care system
setting to examine the effect of a novel behavioral intervention among CKD
patients.
Identification phase: We will identify eligible CKD patients according to health
checkup data.
Intervention phase: We will randomize participants into three groups: “usual
letter,” “nudge-based letter,” and control group.
Follow-up phase: Between the groups, we will compare outcomes of patients'
visiting behaviors to physicians and change in their kidney function according
to medical claims and health checkup data. CKD, chronic kidney disease
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system, all adults aged 40 years or older receive an annual health
checkup with the aim of screening for metabolic syndrome. The parti-
cipants receive notification of the abnormalities in the health checkup
results regarding central obesity, hypertension, diabetes, and hyperli-
pidemia, but it does not include specific information about CKD. There
is no special recommendation to visit physicians for CKD care in the
conventional follow-up.
2.4. Randomization
For this pragmatic trial in the health care system, a research co-
ordinator from the health insurance association assigned eligible par-
ticipants and generated a unique number for each. After stratifying
patients by the timing of screening (quarterly), eGFR (≥60 mL/min
or< 60 mL/min), and urine protein (≥+ or ≤±), we conduct
random allocation with the permuted block method for each stratum.
We randomize participants in a 2:2:1 ratio into the usual letter group,
nudge-based letter group, and control group, respectively.
2.5. Outcomes
Our primary outcome is proportion of patients’ visiting physicians
for 6 months after the intervention, and the secondary outcome is the
change in the eGFR at 2 years after the intervention (Table 1). The
primary outcomes of visiting physicians after the intervention is defined
independently of the presence or absence of the visit before the inter-
vention. Although our definition of visiting physicians after the inter-
vention may include the follow-up visit (re-visit after the intervention
with a history of visiting physicians before the intervention), this does
not affect internal validity of the trial. Follow-up of participants will
end at 2 years after their intervention data are collected or until they
leave the HIA2CE.
The medical claims data from the intervention date to 6 months
after the intervention is used to define visiting behavior. If the parti-
cipants have CKD-related diagnostic codes (Table 2) in their medical
claims during this period, it is considered that they visited physicians
for CKD care. The health checkup data of pre-intervention and post-
intervention (2 years later) is used to define change in the eGFR.
2.6. Statistical analysis
2.6.1. Sample size
Based on past medical claims data and results from the previous
intervention, we assume that the proportions of patients visiting phy-
sicians in each group are 0.15, 0.20, and 0.25 in the control group,
usual letter group, and nudge-based letter group, respectively. We set
the allocation ratio as 1:2:2 for the control group, usual letter group,
and nudge-based letter group, respectively. The sample sizes of 850,
1700, and 1700 patients for each group were determined to achieve
≥80% power overall and for all pairwise comparisons with the chi-
square test by the simulation-based approach. The sample size provides
≥99% power to detect the difference of change from the baseline eGFR
of −3 (standard deviation=10) with a two-sided significance level of
0.05.
2.6.2. Data analysis
We will describe participant characteristics with means and pro-
portions by groups and compare them between groups using analysis of
variance and chi-square tests, and their non-parametric analogs, as
appropriate.
In our analysis to evaluate the effect of the intervention, we will
conduct an intention-to-treat analysis. In our primary analysis, we will
apply a logistic regression model with a dichotomous variable of vis-
iting behavior as the dependent variable, and dummy variables of three
groups and allocation adjustment factors (quarterly timing of the in-
tervention, eGFR, and urine protein) as the independent variables. In
the logistic regression model, we will estimate p-values by omnibus
tests (Wald test) for the differences in outcome (proportion of visits to
physicians) between the groups. If the two-sided p-values by omnibus
tests is< 5%, we will conclude that there are statistically significant
differences in outcome between the groups and will continue to per-
form pairwise comparisons in order to adjust for multiple comparisons
[18]. From the logistic regression model, we will estimate risk differ-
ences and their 95% confidence intervals using the model-based stan-
dardization technique [19]. In a sensitivity analysis, we will adjust for
the presence of lifestyle guidance involved in the usual follow-up after
the health checkup. We will also estimate the proportion and its Wald-
type 95% confidence interval of the primary outcome for each group.
Further, we will estimate the odds ratio and its 95% confidence inter-
vals, and compare them between the groups.
For the confirmatory analysis of the secondary outcome, we will
apply the closed testing procedure. Specifically, only if the two-sided p-
values by the omnibus test of the primary outcome are<5%, we will
conduct the following analysis on the difference of the eGFR. We will
apply a linear regression model with the difference of the eGFR as the
dependent variable, and dummy variables of the three groups and al-
location adjustment factors (quarterly timing of the intervention, eGFR,
and urine protein) as the independent variables. We will estimate p-
values by omnibus tests (Wald test) to determine differences in outcome
(i.e., the difference of eGFR) between the groups. If the two-sided p-
values by omnibus tests are< 5%, we will conclude that there are
statistically significant differences in outcome between the groups and
will continue to conduct pairwise comparisons.
In the subgroup analysis, we will assess the effect of the interven-
tions by the presence of diabetes, age categories (40–49, 50–59, and
≥60 years), sex, and past CKD detection.
2.7. Ethical statements
We are conducting the pragmatic RCT in cooperation with con-
ventional health promotion activities by the health insurance associa-
tion. In this study, we are using routinely collected data, not collecting
additional data, to identify eligible participants, follow them, and assess
their outcomes. The intervention just involves receiving letters to en-
courage patients to visit physicians without any obligation. Therefore,
we received approval from the institutional review board of Kyoto
University (approval number: C1420), and the need for informed con-
sent from the participants was waived.
3. Results
Among 37,775 participants, aged between 40 and 63 years, who
received a health checkup between April and June in 2018, we have
enrolled 1,692 CKD participants (4.5%). The selection process of study
participants during this period is summarized in Fig. 2. Then we ran-
domized 677 participants into the usual letter group, 677 participants





The proportion of participants who visit physicians for CKD care for 6 months
after the intervention
Secondary outcome
Change in the eGFR
Change in the eGFR (mL/min/1.73m2) from the pre-intervention value to the
post-intervention value after 2 years
Proportion of continuous visiting
The proportion of participants who visit physicians for CKD care at least twice
between 1 year and 2 years after the intervention
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
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group. We confirmed that a large number of eligible participants for the
trial could be identified by routinely collected health checkup data.
Table 3 shows participant characteristics in each group. Middle-aged
men are the focus of our study participants. Age, eGFR, proportion of
patients with urine protein ≥1+, blood pressure, and HbA1c level
were similar between the groups. The proportion of patients with a
previous visit was slightly higher in the control group than in the in-
tervention group (no statistical test). We will continue to select eligible
participants by the end of March 2019 and follow them until their
health check-up at 2 years later.
4. Discussion
Large-scale CKD screening is criticized from the viewpoint of cost-
effectiveness [20], but consensus has been obtained that the prevention
of CKD progression is an important public health issue. Because Japan
is a country where pre-diagnosis CKD data have been accumulated by
nationwide health checkups, we could develop an efficient intervention
after CKD screening and assess its effectiveness in the real world.
Conventional CKD screening in Japan can detect potential CKD patients
from the general population but lacks intervention to make them visit
physicians after the screening. Consequently, we designed a pragmatic
trial of nudging CKD patients to visit physicians after screening. The
results from this trial will contribute to filling the gap between
screening and subsequent medical interventions and will also be a
model for a “learning health system” that utilize the routinely collected
health data to improve the health care system.
Our pragmatic RCT is designed in the health care system. By taking
advantage of having large-scale health checkup data in Japan, we are
conducting this implementation research to improve patients' visiting
behaviors to physicians after CKD screening. Since it is usually difficult
to allocate intervention, i.e., whether to provide medical treatment, in a
high-risk population, our intervention to encourage patients to visit
physicians by just sending them a letter is a feasible and realistic ap-
proach for the prevention of CKD progression. Our intervention is in-
expensive and can be implemented for other health issues in the future.
We will only use routinely collected data from the health care system to
identify eligible participants, follow them, and measure their outcomes.
This makes it possible to perform a large-scale pragmatic RCT involving
a wider population at a lower cost. Our pragmatic RCT can assess both
short-term outcomes of patients’ visiting behavior and long-term
Table 2
Chronic kidney disease-related diagnostic codes.
ICD-10 codes
Chronic kidney disease N170, N171, N172, N178, N179, N180, N188, N189, N19, N990
Tubulointerstitial nephritis N110, N111, N118, N119, N12, N140, N141, N142, N143, N144, N150
Chronic glomerular nephritis N002, N003, N004, N006, N007, N009, N012, N014, N016, N017, N019, N028, N029, N030, N032, N033, N034, N036, N037, N039, N040,
N042, N044, N046, N049, N050, N051, N052, N053, N054, N055, N056, N057, N058, N059, N069, N079, N085
Diabetic nephropathy E102, E112, E132, E142
Hypertensive nephrosclerosis I129, I120
Polycystic kidney disease Q613
Fig. 2. Selection process of study participants, from 2018 April to 2018
June. Among 37,775 participants, aged between 40 and 63 years, who received
a health checkup between April and June in 2018, we have enrolled 1,692 CKD
participants (4.5%). CKD, chronic kidney disease; eGFR, estimated glomerular
filtration rate; ESRD, end stage renal disease.
Table 3
Participant characteristics.
Control group (N=338) Usual letter group (N=677) Nudge-based letter group (N=677)
Age, mean (SD), years 53.7 (6.6) 53.8 (6.5) 53.6 (6.6)
Male sex, n (%) 313 (92.6) 617 (91.1) 623 (92.0)
eGFR, mean (SD), mL/min/1.73 m2 68.7 (15.2) 68.1 (16.0) 68.7 (15.9)
Urine protein ≥+, n (%) 214 (63.3) 429 (63.4) 429 (63.4)
SBP, mean (SD), mmHg 129.8 (17.9) 129.9 (18.7) 130.2 (18.7)
DBP, mean (SD), mmHg 81.9 (13.0) 82.2 (12.9) 82.0 (13.0)
HbA1c, mean (SD), % 6.1 (1.1) 6.0 (1.1) 6.10 (1.22)
Hypertension, n (%) 138 (37.2) 252 (40.8) 264 (39.0)
Diabetes, n (%) 66 (19.5) 100 (14.8) 108 (16.0)
Current smoking, n (%) 120 (35.5) 217 (32.1) 229 (33.8)
Previous visiting,a n (%) 19 (5.6) 31 (4.6) 28 (4.1)
SD, standard deviation; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.
DBP, diastolic blood pressure; HbA1c, glycated hemoglobin A1c; CKD, chronic kidney disease.
a Previous visiting was defined as proportion of visiting to physicians within 6 months before health checkup.
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outcome of renal function through analysis plans, in which we can
manage statistical multiplicity.
Another major feature of this trial is to examine the effect of a nudge
approach on patients' behaviors in one important issue of public health.
Many of the interventional studies in public health have focused on the
effect of mandatory interventions (restricting a patient's choice) or fi-
nancial incentives. Additionally, these studies have been conducted on
some limited issues, including smoking and obesity. In behavioral
economics, an increasing number of studies has investigated the effect
of the nudge approach, especially in the United States and Europe
[16,21–23]. However, many of these studies have also focused on
smoking and obesity, or when studying the other clinical issues, the
study subjects have usually been limited to patients in a certain hos-
pital. Therefore, the present trial is unique in that it is investigating the
effect of the nudge approach in Japan, an unexamined clinical issue,
and evaluating subjects from a wider range of regions.
Investigating the effect of the nudge approach is recommended by
the Japanese government, which followed the Behavioral Insights Team
in the United Kingdom and founded the Behavioral Sciences Team in
2017, to apply behavioral economics and nudge in various policy fields,
including health policy. As we explained earlier, we considered pa-
tients’ behavioral characteristics and designed the letter accordingly.
Thus, our nudge approach can be expected to be cost-effective.
There are several limitations to this pragmatic RCT. First, we will
use only routinely collected data. Avoiding additional data collection
dramatically decreases the cost and effort, and enables such a large-
scale pragmatic RCT to be conducted. However, we cannot assess un-
measured factors, which are not included in the health checkup and
medical claims. Second, we will use a one-time measurement of kidney
function to identify CKD participants at screening. The original defini-
tion of CKD is a continuous renal function deficiency, which needs at
least two time measurements of kidney function [24,25]. In previous
clinical studies, a one-time measurement of kidney function is often
used to define CKD, which is validated as a risk factor in identifying the
population with renal risk [26,27]. Further, our intervention to en-
courage potential CKD participants to visit physicians is clinically rea-
sonable to confirm the presence of CKD by performing re-tests of kidney
function. Third, we will define our outcomes of visiting behavior by
CKD-related diagnostic codes in medical claims data, and thus, patients
who receive CKD care without CKD-related diagnostic codes will be
misclassified. For example, CKD patients with hypertension might re-
ceive CKD care without CKD-related diagnostic codes. However, we
expect this misclassification to be a non-difference between allocation
groups, and the effect of the intervention will not be biased by this
factor. Fourth, the trial is open-labeled without blinding. However,
because we will use routinely collected data to measure study outcomes
based on a pre-specified definition, outcome assessment will be less
susceptible to non-blinding. Fifth, some participants are excluded be-
cause of the absence of CKD screening. In Fig. 2 and 92.3% of partici-
pants received CKD screening. Whether a participant receives CKD
screening in addition to the mandatory health checkup items is decided
by each company and cannot be decided by the individual participant.
Therefore, the effect of excluding a small portion of participants
without CKD screening is limited. Finally, we will include the middle-
aged male-focused Japanese population in this trial. Although this
pragmatic RCT in the health care system will include a broader popu-
lation than a conventional trial, generalizability to other populations is
limited.
5. Conclusions
With prevalence of 4.5% for CKD and only 7–8% for visiting phy-
sicians before screening, it is apparent that the patients who are not
under the care of a physician continue to have deteriorating kidney
function. We anticipate that with an increase in the proportion of pa-
tients visiting physicians following screening, clinical management will
be instituted in time and patient outcomes optimized. This will also
ensure returns on investment in CKD screening programs. The inter-
vention we will examine is a low-cost method that can be implemented
to other health issues in the future. The trial will also show the model
for utilizing routinely collected data to assess the effect of a public
health intervention in the real world.
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